AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03394482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 5 mg clinical formulation
Description: Lu AF35700 tablets 5 mg oral single dose
Study NCT03394482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 5 mg commercial formulation
Description: Lu AF35700 tablets 5 mg oral single dose
Study NCT03394482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 10 mg clinical formulation
Description: Lu AF35700 tablets 10 mg oral single dose
Study NCT03394482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 10 mg commercial formulation
Description: Lu AF35700 tablets 10 mg oral single dose
Study NCT03394482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 20 mg clinical formulation
Description: Lu AF35700 tablets 20 mg oral single dose
Study NCT03394482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 20 mg commercial formulation
Description: Lu AF35700 tablets 20 mg oral single dose
Study NCT00735787 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
Study NCT00735787 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
Study NCT00735787 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
Study NCT03006744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological awareness training
Description: Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
Study NCT03006744 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reading enjoyment training
Description: Training on how to make reading enjoyable for children.
Study NCT03251508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut OIT
Description: Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
Study NCT01786954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry
Study NCT01786954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonopen applanation
Study NCT01786954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation
Study NCT04234035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision aid to facilitated shared decision-making
Study NCT04234035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Educational Material (informational pamphlet)
Description: Pamphlet with information about kidney stones
Study NCT04234035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Educational Material (informational pamphlet)
Description: Pamphlet with information about kidney stones
Study NCT03583138 — intervention group
Intervention type: DRUG
Intervention: buprenorphine
Description: To provide buprenorphine for 12 months for those who are interested in receiving it.
Study NCT03879044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
Study NCT03790358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: Drug will be administered in solution form.
Study NCT03790358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: Drug will be administered in solution form.
Study NCT01603797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered acceptance and commitment therapy
Description: The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
Study NCT01603797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided internet-delivered acceptance and commitment therapy
Description: The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
Study NCT02687347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine
Description: Oral morphine is the active comparator. It is not a placebo intervention
Study NCT01464632 — intervention group
Intervention type: DEVICE
Intervention: EPIK™ uni-compartmental knee
Description: This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
Study NCT02117739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Patches containing dapsone gel will be applied to the skin.
Study NCT02117739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel vehicle
Description: Patches containing dapsone gel vehicle will be applied to the skin.
Study NCT03688698 — intervention group
Intervention type: RADIATION
Intervention: PET/MRI
Description: PET/MRI scans
Study NCT00841048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: ascending multiple doses(start dose 75mg od), oral suspension
Study NCT00841048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01328041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: 50 mg twice daily
Study NCT02446470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus Tarsi approach
Description: A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
Study NCT02446470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensile Lateral approach
Description: An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
Study NCT02968381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Intervention
Description: Telephone coaching sessions, use of guided imagery and website.
Study NCT02968381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Telephone coaching using standard cognitive behavioral methods
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation of Virtual Actions
Description: If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation
Description: If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acceptability questionnaire
Description: It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation of Virtual Actions (step 4)
Description: If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performing Virtual Actions
Description: If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptic stimulation
Description: According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
Study NCT02909504 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
Study NCT04441164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without haptic stimulation
Description: Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
Study NCT04436471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: adenoviral-based vaccine against SARS-CoV-2
Study NCT04414124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KB109 + Self Supportive Care (SSC)
Description: KB109 is a novel glycan
Study NCT04414124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self Supportive Care (SSC) Alone
Description: Self Supportive Care (SSC) Alone
Study NCT03675425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1: non chest shielding
Description: non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
Study NCT03675425 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 2: chest shielding
Description: chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
Study NCT02420054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
Study NCT01366612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
Description: Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1
Study NCT01366612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
Description: Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1
Study NCT03262207 — intervention group
Intervention type: OTHER
Intervention: Extraction genomic DNA
Study NCT02088736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraosseous
Study NCT02088736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous
Study NCT03262207 — intervention group
Intervention type: OTHER
Intervention: Analysis of methylation profiles of numerous GSI and TE
Study NCT03262207 — intervention group
Intervention type: OTHER
Intervention: Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)
Study NCT03262207 — intervention group
Intervention type: OTHER
Intervention: Method of protein detection by immunostaining and flow cytometry
Study NCT03562234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR
Description: Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
Study NCT03562234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LiMAx
Description: Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
Study NCT00751309 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Post-transplantation observational study
Study NCT00628589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Description: Inhaled loxapine 5 mg
Study NCT00628589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Description: Inhaled loxapine 10 mg
Study NCT00628589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled placebo
Study NCT01460719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ
Study NCT00354107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody SGN-30
Description: Given IV
Study NCT00354107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study NCT00354107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00354107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00354107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00354107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT00354107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00354107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00354107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03627065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily at the protocol-defined dose.
Study NCT02303782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015
Study NCT02303782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza (azacitidine)
Study NCT03542916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-40001 60ug
Description: CJ-40001 60ug SC, IV injection
Study NCT03542916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60ug
Description: NESP 60ug SC, IV injection
Study NCT03470129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fissure sealing
Description: sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
Study NCT03470129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fissure sealing
Description: sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
Study NCT03132519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
Study NCT03132519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
Study NCT04545320 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care control group
Description: Health education
Study NCT04545320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT group
Description: Once-a-week HIIT
Study NCT04545320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT group
Description: Once-a-week MICT
Study NCT03066362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography-Doppler
Description: Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
Study NCT01960088 — intervention group
Intervention type: DRUG
Intervention: HPV vaccine
Study NCT03739957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPCO Media Kit
Description: Telemonitoring system for patients with COPD
Study NCT02830607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xiaomi Mi Band
Description: participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
Study NCT05394532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Common Education
Study NCT01901679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 200 mg PO BID
Study NCT02008461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Study NCT02008461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin injection
Study NCT03819023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respilife monitor
Description: Respilife monitor
Study NCT00314028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus on the Future
Description: Focus on the Future is an educational program designed to promote proper condom use.
Study NCT02420054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time control
Description: Time control period with no change in eating habits.
Study NCT03336775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
Study NCT01813084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 single dose
Description: Safety and tolerability of single escalating doses
Study NCT01813084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo single dose
Description: Safety and tolerability of single escalating doses
Study NCT01813084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses